A practical radiosynthesis of a tritium-labelled fluorocombretastatin

Zybrestat (combretastatin A-4 disodium diphosphate) is currently in clinical trials as an antivascular anticancer agent. A similar fluorinated agent has shown promise as an antivascular agent and a radiolabelled version would enable further understanding of its biological activities. Herein is described the synthesis of a tritiated fluorinated analogue of Zybrestat.